Chao Jeffrey Yung-Chuan, Chang Hsin-Chuan, Jiang Jeng-Kai, Yang Chih-Yung, Chen Fang-Hsin, Lai Yo-Liang, Lin Wen-Jen, Li Chia-Yang, Wang Shu-Chi, Yang Muh-Hwa, Lin Yu-Feng, Cheng Wei-Chung
Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Department of Radiation Oncology, Taichung Veterans General Hospital, Taichung, Taiwan.
Comput Struct Biotechnol J. 2021 Jul 1;19:3922-3929. doi: 10.1016/j.csbj.2021.06.044. eCollection 2021.
Colorectal cancer (CRC) results from the uncontrolled growth of cells in the colon, rectum, or appendix. The 5-year relative survival rate for patients with CRC is 65% and is correlated with the stage at diagnosis (being 91% for stage I at diagnosis versus 12% for stage IV). This study aimed to identify CRC driver genes to assist in the design of a cancer panel to detect gene mutations during clinical early-stage screening and identify genes for use in prognostic assessments and the evaluation of appropriate treatment options. First, we utilized bioinformatics approaches to analyze 354 paired sequencing profiles from The Cancer Genome Atlas (TCGA) to identify CRC driver genes and analyzed the sequencing profiles of 38 patients with >5 years of follow-up data to search for prognostic genes. The results revealed eight driver genes and ten prognostic genes. Next, the presence of the identified gene mutations was verified using tissue and blood samples from Taiwanese CRC patients. The results showed that the set identified gene mutations provide high coverage for driver gene screening, and , and could be detected in blood as ctDNA test targets. We further found that gene mutation was correlated with prognosis in CRC (log-rank p-value = 0.02), and that mutations of could be identified in ctDNA samples. These findings may be of value in clinical early cancer detection, disease monitoring, drug development, and treatment efforts in the future.
结直肠癌(CRC)是由结肠、直肠或阑尾中细胞的无节制生长所致。CRC患者的5年相对生存率为65%,且与诊断时的分期相关(诊断为I期时为91%,而IV期时为12%)。本研究旨在识别CRC驱动基因,以协助设计一个癌症检测板,用于在临床早期筛查期间检测基因突变,并识别用于预后评估和合适治疗方案评估的基因。首先,我们利用生物信息学方法分析了来自癌症基因组图谱(TCGA)的354对测序图谱,以识别CRC驱动基因,并分析了38例有超过5年随访数据患者的测序图谱,以寻找预后基因。结果揭示了8个驱动基因和10个预后基因。接下来,利用来自台湾CRC患者的组织和血液样本验证了所识别基因突变的存在。结果表明,所识别的基因突变集为驱动基因筛查提供了高覆盖率,并且可以在血液中作为循环肿瘤DNA(ctDNA)检测靶点被检测到。我们进一步发现, 基因突变与CRC的预后相关(对数秩p值 = 0.02),并且可以在ctDNA样本中识别出 的突变。这些发现可能在未来的临床早期癌症检测、疾病监测、药物开发和治疗工作中具有价值。